Papillary Renal Cell Carcinoma Terminated Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0030667 (Papillary Renal Cell Carcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00098618Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTreatment